Shares of Veru VERU rose 7% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 83.33% over the past year to ($0.01), which beat the estimate of ($0.04).
Revenue of $9,943,000 rose by 42.53% year over year, which missed the estimate of $10,970,000.
Looking Ahead
Veru hasn't issued any earnings guidance for the time being.
Veru hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 13, 2020
Time: 06:49 PM ET
Webcast URL: https://verupharma.com/investors/presentations-conference-calls/
Price Action
52-week high: $4.74
52-week low: $1.50
Price action over last quarter: down 16.05%
Company Overview
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.